nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-56043F8B·Framework v5.9·Pipeline v0.4·Evaluated 08 Oct 2026·OECD: 3.2 Clinical medicine·Subfield: Psychiatry and Mental health·Basis: Full text·Type: Prediction or prognostic modeling

Estimating the time course of biomarker changes in Alzheimer's disease.

Raket et al.Raket, Binette, Mattsson-Carlgren et al.·2025·Brain : a journal of neurology·10.1093/brain/awaf413 ↗

Primary claim

The proposed staging approach was found to produce stronger correlations with unseen cognitive measures and biomarkers compared to alternative staging methods, including amyloid and tau PET clocks (all pairwise P < 0.05).

Tentative · the stated universal significance conflicts with the non-significant GRACE comparison and rests on internal correlation-based validation
In brief

A useful cross-cohort Alzheimer’s biomarker timeline with broad modality coverage, constrained by internal validation that does not establish universal staging superiority.

ReliabilityCaveats4 of 4 checks completeRead the 2 entries ↓
Fragile — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.
Abstract

Recent advancements in biomarkers have transformed Alzheimer's disease (AD) diagnosis from being purely symptom-based to include biological criteria. With new treatments targeting the core biology of Alzheimer's disease, understanding the timeline of biological changes is crucial as the disease progresses over decades. Longitudinal data from amyloid-beta (Aβ) PET and cognitive tests [Mini-Mental State Examination (MMSE) and Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog)] from the Alzheimer's Disease Neuroimaging Initiative (n = 1448) and BioFINDER (n = 2088) were used to stage patients against an estimated continuous disease timeline (predicted time since Aβ-PET positivity). The estimated timeline was validated by comparing correlations with unseen biomarkers and cognitive measures against alternative staging approaches. Trajectories for plasma, CSF, MRI and PET biomarkers, measuring Aβ, tau and neurodegeneration, were mapped along this Alzheimer's disease continuum. The proposed staging approach was found to produce stronger correlations with unseen cognitive measures and biomarkers compared to alternative staging methods, including amyloid and tau PET clocks (all pairwise P < 0.05). Findings related to biomarker trajectories were highly consistent across cohorts. The period from Aβ-PET positivity to end-stage Alzheimer's disease dementia (MMSE = 0) was estimated at 20-25 years, with a presymptomatic phase of 7-11 years. CSF Aβ42/Aβ40 became abnormal about a year before Aβ-PET positivity, CSF phosphorylated-tau (p-tau)231, p-tau217 and plasma phosphorylated/neuritic plaque-tau217 1-3 years after, and tau-PET about 8 years after. Neurodegenerative biomarkers, such as hippocampal volume, became clearly abnormal in early dementia stages, 14-16 years after Aβ-PET positivity. The progression from initial biomarker abnormality to severe Alzheimer's disease spans two decades. Disease progression modelling elucidates the evolution of AD biomarkers and cognition, highlighting the relative timing of biomarker abnormalities. These models can determine disease stages, aiding in prognosis and the evaluation of disease-modifying treatments.

Key Claims

Primary finding · Tentative

The proposed staging approach was found to produce stronger correlations with unseen cognitive measures and biomarkers compared to alternative staging methods, including amyloid and tau PET clocks (all pairwise P < 0.05).

Fragile — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.

the stated universal significance conflicts with the non-significant GRACE comparison and rests on internal correlation-based validation

Abstract; Results, Disease progression modeling results and validation
Quote verified
Secondary · Tentative

The period from Aβ-PET positivity to end-stage Alzheimer's disease dementia (MMSE = 0) was estimated at 20-25 years, with a presymptomatic phase of 7-11 years.

model-based extrapolation is sensitive to sparse late-stage data, increasing variance, and informative dropout

Abstract; Results, Disease progression modeling results and validation; Discussion, limitations paragraph
Quote verified
Secondary · Supported

CSF Aβ42/Aβ40 became abnormal about a year before Aβ-PET positivity, CSF phosphorylated-tau (p-tau)231, p-tau217 and plasma phosphorylated/neuritic plaque-tau217 1-3 years after, and tau-PET about 8 years after.

bootstrap-timed model estimates show consistent ordering across cohorts, though abnormality thresholds and Aβ-status rules shape timing

Abstract; Results, Biomarker trajectories; Fig. 4
Quote verified
Secondary · Supported

Findings related to biomarker trajectories were highly consistent across cohorts.

trajectory ordering and abnormality timings broadly agree across ADNI and BioFINDER despite different measurement systems

Abstract; Results, Biomarker trajectories; Figs 3–4
Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#contribution

Broad cross-modality biomarker timeline

Plasma, CSF, MRI, amyloid-PET, and tau-PET measures are placed on a shared predicted time-since-Aβ-PET-positivity axis, providing fine-grained relative timing across disease domains.

↳ Results, Biomarker trajectories; Figs 3–4

#methodological rigour

Replication across two large cohorts

The broad ordering and abnormality timings are reported as highly consistent across ADNI and BioFINDER despite differences in assays, tracers, processing, and cognitive measures.

↳ Results, Biomarker trajectories; Figs 3–4 and Supplementary Fig. 9

#methodological rigour

Relevant comparator and sensitivity analyses

The model is compared with clinical staging variables, amyloid and tau clocks, GRACE, and LTJMM, while random-effect sub-models and bootstrap timing intervals provide additional checks.

↳ Methods, Model validation; Results, Tables 2–3 and Supplementary Tables 1–4

Limitations

#reporting

Universal superiority claim is inconsistent

The Abstract says all pairwise comparisons were significant, but Results report P = 0.1796 against GRACE. The conclusion’s broad superiority claim therefore exceeds the reported comparison evidence.

↳ Abstract; Results, Disease progression modeling results and validation; Discussion, concluding paragraph

#methodological rigour

Validation does not test prognosis

Validation uses correlations with other measures from the same source cohorts rather than held-out subjects, future outcomes, or operational decisions. This does not establish the claimed prognostic or trial-staging utility.

↳ Methods, Model validation; Discussion, clinical application claims

#positioning

Absolute durations remain model-dependent

Residual variance increases with disease age, late-stage estimates may be lengthened by informative dropout, and the model assumes one multivariate trajectory. These issues particularly qualify the 20–25-year duration estimate.

↳ Results, conditional residuals; Discussion, limitations paragraph

Does this match your read? Add your assessment ↓

Nabu Commentary

The contribution is driven by the common timeline spanning fluid and imaging biomarkers and by the consistency reported across ADNI and BioFINDER. Methodological credit comes from direct comparator analyses, random-effect sub-models, BIC-based trajectory fitting, and bootstrap intervals. The score is constrained by internal construct validation over correlated endpoints and by the absence of prospective or held-out-subject testing. The Abstract and conclusion also require revision because the universal superiority language is inconsistent with the non-significant GRACE comparison and does not establish accuracy against a biological-time ground truth.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
3.6±0.2

Contribution
3.9

The study extends a semiparametric latent-time model and maps a broad set of plasma, CSF, MRI, and PET biomarkers onto a common timeline in two cohorts. The advance is meaningful but remains a model-dependent refinement of an established biomarker cascade.

Introduction, final paragraph; Methods, Disease progression modeling; Results, Figs 3–4
Methodological Rigour
3.4

The analysis includes two cohorts, multiple comparator methods, random-effect sub-model comparisons, BIC-based trajectory selection, and bootstrap intervals. Validation remains internal to the source cohorts and compares many dependent correlations without uncertainty around the performance differences.

Methods, Model validation and Estimating biomarker trajectories; Results, Tables 2–4 and Supplementary Tables 1–4
Reporting
3.5

The paper follows a coherent sequence from model construction through validation and biomarker timing. Its Abstract and conclusion overstate comparative performance because GRACE was not significantly outperformed and no time-based ground truth establishes the “most accurate” description.

Abstract; Results, Disease progression modeling results and validation; Discussion, concluding paragraph

“the difference did not reach statistical significance compared to the GRACE model”

Positioning
3.9

The paper engages directly with PET clocks, latent-time models, autosomal-dominant evidence, and alternative timing estimates. Its limitations discussion traces single-trajectory assumptions, age effects, and informative dropout to the interpretation of late-stage duration.

Introduction; Discussion, paragraphs comparing Jia et al. and Therneau et al.; Discussion, limitations paragraph

Reliability

Caveats4 of 4 checks


Results checkNoted
  • The proposed staging approach was found to produce stronger correlations with unseen cognitive measures and biomarkers compared to alternative staging methods, including amyloid and tau PET clocks (all pairwise P < 0.05): "The proposed staging approach was found to produce stronger correlations with unseen cognitive measures and biomarkers compared to alternative staging methods, including amyloid and tau PET clocks (all pairwise P < 0.05)." (Abstract) vs "The predicted disease showed numerically stronger average correlations than GRACE disease time (P = 0.1796) and LTJMM disease time (P = 0.0001)." (Results — Disease progression modeling results and validation). The reported GRACE comparison has P = 0.1796 > 0.05, contradicting the unrestricted statement that all pairwise comparisons with alternative staging methods were significant. → Not supported by the paper's own data
Reporting and transparencyNoted

The diagnosis-imputation sensitivity analysis is explicitly reported as data not shown, leaving its stated result without presented supporting estimates.

Conflict of interest: not stated · Ethics approval: declared · Data availability: declared · Code availability: declared

Reference IntegrityClean

69 references in manuscript 65 of 65 checkable references found in an index 4 have no canonical index record — counted, but not index-checkable 1 reference confirmed by manual review

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Neurological · Alzheimer's disease and other dementias
Type of advanceMethodological
Route to useSuggested
AdvanceAdvances
BeneficiariesLarge
CitationsToo early
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessValidated
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The primary claim about superior staging correlations was confirmed in two independent large cohorts, ADNI and BioFINDER, with highly consistent biomarker trajectories across both.

From the paper
“These models can determine disease stages, aiding in prognosis and the evaluation of disease-modifying treatments.”

The paper names real-world uses of its staging model, namely prognosis and evaluation of disease-modifying treatments, but does not specify who would act on them.

Pathway

Clinicians and clinical trial teams could use the predicted time since Aβ-PET positivity to stage patients for prognosis and to select patients in trials of disease-modifying treatments.

Barrier

The model assumes a single disease trajectory and non-informative missing data, and requires Aβ PET and cognitive data, so its routine clinical use awaits demonstration outside research cohorts.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Effect of intensive blood pressure control on cognitive outcomes and brain structures in adults with type 2 diabetes: prespecified analysis of secondary outcomes of BPROAD randomised controlled trial

    Wang, Xu, Xu, et al. · 2026 · Clinical medicine

    Primary claim

    no statistically significant difference in incidence of a composite of all cause dementia or mild cognitive impairment was observed among adults with type 2 diabetes receiving standard treatment of SBP and intensive treatment

    Well-supported
    Evidence Score
    4.1±0.1
    Reliability
    Caveats
  2. Smoking and dementia risk: an updated systematic review and meta-analysis of 61 prospective cohort studies and implications for tobacco control

    Mario Siervo, Jacob Brain, Sarah Beasley, et al. · 2026 · Health sciences

    Primary claim

    Current smoking was associated with increased risk of all-cause dementia (RR 1.31 [95% CI 1.23–1.39]; number of studies (k) = 39), Alzheimer's disease (1.40 [1.08–1.80]; k = 15), and vascular dementia (1.52 [1.20–1.93]; k = 9).

    Supported
    Evidence Score
    3.3±0.2
    Reliability
    Caveats
  3. Decreased awareness of cognitive decline is associated with multimodal Alzheimer's disease biomarkers in cognitively unimpaired individuals

    2026 · Clinical medicine

    Primary claim

    decreased ACD was associated with greater AD pathological burden

    Supported
    Evidence Score
    3.2±0.2
    Reliability
    Caveats

How the rubric works →